APCONIX
a better decision

Acuity Target Safety Assessments (TSAs)

Derisking Target Safety

Created by toxicologists and enabled by advanced data science to guide better decision making

A Tailored Acuity TSA Will:

- Increase your knowledge of target and modality related safety risks
- Provide a risk mitigation plan to inform toxicology study design
- Maximise the use of your limited resources
- Support timely and informed decision making

acuity
Expert-driven – *AI-enabled*

"Working with ApconiX was effortless! They have provided high quality target safety assessments with a focus on comprehensive interpretation of findings. The information provided has helped contribute to decisions on activities when moving early molecules forward."

Gilead

Up to 50% of drug safety failures are attributable to target related effects

What Is a Target Safety Assessment?

A target safety assessment (TSA) is an integrated evidence based report that identifies potential risks associated with modulating a biological target. A TSA combines public domain information with the expertise of an experienced toxicologist into a concise report.

Why Are TSAs Important in Drug Discovery and Development?

Understanding potential safety liabilities associated with a target early in a project helps you anticipate and manage issues before they arise. An Acuity TSA forms the basis of a risk mitigation plan including the ranking of risks and potential next steps.

Acuity TSAs: From Key Risks to a Complete Risk Assessment

Customised reports including:

- Mini TSA
- Comprehensive TSA
- Modality and asset focused reports



Acuity TSA Deliverables

- Target and modality related risks
- Translational issues and off target risks
- Mitigation plans with ranking of risks and potential next steps

We also offer consultancy and support in predictive safety, mechanistic and investigative toxicology and data science

"With many thanks - this target safety assessment was exactly what we needed and we are very pleased with the quality of the work that went into this."

Head of Translational Science,
UK Biotech Company

We are an integrated team of toxicologists and data scientists with extensive nonclinical toxicology experience

Safety Science Experts Include:

Professor Ruth Roberts

Cofounder of ApconiX: Ruth has over 25 years of experience in leading drug safety. Ruth is also chair and Director of Drug Discovery at the University of Birmingham, UK and previously Global Head of Regulatory Safety at AstraZeneca.

Dr James Sidaway

Head of Safety Science: James is an experienced and innovative toxicologist having worked for over 20 years in the pharmaceutical industry with AstraZeneca and as an independent consultant. As a molecular investigative toxicologist he helped resolve safety issues for a wide range of drug discovery and development projects across the major therapy areas.

Dr Claire Sadler

Senior Project Toxicologist: Claire is an experienced project toxicologist and former Director of Discovery Safety within AstraZeneca. Claire specialises in early project safety assessment, identifying and mitigating risks from target identification through to early clinical trials.

Dr Nicholas Coltman

Deputy Head of Safety Science: Nic holds a PhD in in vitro nonclinical toxicological research (hepatotoxicity, genotoxicity and advanced in vitro models) through a BBSRC iCASE Scholarship with Sygnature Discovery Ltd at the University of Birmingham. Nic has invaluable industry experience first at Envigo and then at Sygnature Discovery.

Dr Helen Garside

Senior Toxicologist: Helen has over 15 years of experience in the pharmaceutical industry focused on predictive and mechanistic toxicology. She has expertise in early project toxicology gained through roles in discovery safety and safety pharmacology, supporting projects across multiple therapy areas.

Dr Sean Hammond

Immunotoxicology Lead: Sean holds a PhD in immunopharmacology from the University of Liverpool focused on developing experimental and conceptual means to address T cell mediated hypersensitivity reactions. He has long standing links with drug safety research at Liverpool where he received the Syngenta prize for pharmacology and where he maintains an academic profile.

Individually tailored to the needs of each project and client



50 tissue multi species analysis

12 organ systems reported

Experience of 100s of targets

Modality specific protocols

THE KING'S AWARDS FOR ENTERPRISE 2024 INTERNATIONAL TRADE

THE QUEEN'S AWARDS FOR ENTERPRISE: INTERNATIONAL TRADE 2022

Contact the ApconiX team for more details

hello@apconix.com | www.apconix.com

Mereside | Alderley Park | Alderley Edge | Cheshire | SK10 4TG | UK